Department of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX, USA.
Department of Pharmaceutics, University of Washington, Seattle, WA, USA.
Sci Rep. 2018 Oct 5;8(1):14882. doi: 10.1038/s41598-018-33099-2.
The adoption of a new technology into basic research, and industrial and clinical settings requires rigorous testing to build confidence in the reproducibility, reliability, robustness, and relevance of these models. Tissue chips are promising new technology, they have the potential to serve as a valuable tool in biomedical research, as well as pharmaceutical development with regards to testing for efficacy and safety. The principal goals of this study were to validate a previously established proximal tubule tissue chip model in an independent laboratory and to extend its utility to testing of nephrotoxic compounds. Here, we evaluated critical endpoints from the tissue chip developer laboratory, focusing on biological relevance (long-term viability, baseline protein and gene expression, ammoniagenesis, and vitamin D metabolism), and toxicity biomarkers. Tissue chip experiments were conducted in parallel with traditional 2D culture conditions using two different renal proximal tubule epithelial cell sources. The results of these studies were then compared to the findings reported by the tissue chip developers. While the overall transferability of this advanced tissue chip platform was a success, the reproducibility with the original report was greatly dependent on the cell source. This study demonstrates critical importance of developing microphysiological platforms using renewable cell sources.
将新技术应用于基础研究、工业和临床环境需要进行严格的测试,以建立对这些模型的可重复性、可靠性、稳健性和相关性的信心。组织芯片是一种很有前途的新技术,它们有可能成为生物医学研究以及药物开发中测试疗效和安全性的有价值的工具。本研究的主要目的是在一个独立的实验室中验证先前建立的近端小管组织芯片模型,并扩展其在测试肾毒性化合物方面的应用。在这里,我们评估了组织芯片开发商实验室的关键终点,重点关注生物学相关性(长期活力、基线蛋白和基因表达、氨生成和维生素 D 代谢)和毒性生物标志物。组织芯片实验与传统的 2D 培养条件平行进行,使用两种不同的肾近端小管上皮细胞来源。然后将这些研究的结果与组织芯片开发商报告的结果进行比较。虽然这个先进的组织芯片平台的整体可转移性是成功的,但与原始报告的重现性在很大程度上取决于细胞来源。这项研究表明,使用可再生细胞来源开发微生理平台至关重要。